Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SW1115C3 in advanced solid tumors
NCT05198752Phase 1Unknown
- Sponsor
- Stemirna Therapeutics
- Start
- Mar 2022
- Primary completion
- Dec 2023
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of SW1115C3 in solid tumor, sponsored by Stemirna Therapeutics. Primary endpoint: Dose-limiting toxicity incidence at 21 days. Status: unknown.
02
Drugs
SW1115C3
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05198752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05198752.